Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...

Zaposlitev v Novartisu v Sloveniji V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Treating advanced prostate cancer demands more than clinical progress—it demands a new era of care, fueled by relentless innovation, collaborative efforts, and an unwavering push toward personalized ...

ノバルティス ファーマ株式会社について ノバルティス ファーマ株式会社は、スイス・バーゼルに本拠を置く革新的医薬品のグローバル製薬企業ノバルティスの日本法人です。ノバルティスは、より充実した健やかな毎日のために、「医薬の未来を描く（Reimagining Medicine）」ことを追求してい ...

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) ...

主な役割責任早期化合物の安全性評価を行いチームへ適切に評価内容を伝える。承認申請資料を作成し，当局からの照会回答を含む承認申請全般に責任をもつ。治験届に関する資料作成を行い，当局からの照会対応を含む治験届業務全般に責任をもつ。当局に対する相談について非臨床安全性 ...

this week to discuss new ideas to transform healthcare. Our Novartis leaders engaged in discussions showcasing the company's scientific breakthroughs—and shared something just as urgent: The story of ...